BC
CCCC icon

Bridgefront Capital’s C4 Therapeutics CCCC Stock Holding History

Bridgefront Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,925
Closed -$120K – 322
2022
Q2 		$120K Buy
+15,925
New +$140K 0.13% 260

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Bridgefront Capital's CCCC Position: Q3 2022 in Review

Bridgefront Capital sold out of C4 Therapeutics (CCCC) in Q3 2022, closing a stake of 15,925 shares — an estimated $120K sold.

Bridgefront Capital first reported a position in CCCC in Q2 2022 and held it in 1 quarter. The position peaked at $120K in Q2 2022. 114 funds tracked by Wall St. Rank hold CCCC as of Q3 2022.

  • Bridgefront Capital reported no remaining C4 Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Bridgefront Capital sold 15,925 C4 Therapeutics shares in Q3 2022, an estimated $120K.
  • Bridgefront Capital first reported a position in C4 Therapeutics in Q2 2022 and held it in 1 quarter.
  • Bridgefront Capital's C4 Therapeutics position peaked at $120K in Q2 2022.
  • 114 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2022.

Based on Bridgefront Capital's 13F filing for Q3 2022, filed 29 Nov 2022.